New Life Medical Services is committed to remaining fully compliant with all new Food and Drug Administration (FDA) regulations. Our team is taking this opportunity to review the FDA’s latest regenerative medicine policy framework. During this time, we will audit all of our products, processes, and services to ensure they are compliant.
Once we have determined all of our new processes satisfy FDA regulations, we will submit investigational new drug (IND) and premarket approval requirements for each of our products. Our team will keep you informed as we learn more.
We thank you for your understanding and ask that you submit any questions regarding our processes using the contact form below.